Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A new Locations section lists recruitment sites in Illinois, Iowa, Maryland, Michigan, Minnesota, and Wisconsin, and the page revision is updated to v3.3.3. The HHS Vulnerability Disclosure link and older location entries were removed.
    Difference
    0.7%
    Check dated 2025-12-23T22:04:11.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    Revision changed from v3.2.0 to v3.3.2 with no visible changes to the Study Details page, its content, or study data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-25T11:49:36.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The page removed a generic federal operating status notice. This change does not affect the study details or how to participate.
    Difference
    0.3%
    Check dated 2025-11-18T07:17:54.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The screenshots show only minor formatting and timestamp updates, with no changes to eligibility criteria, study design, endpoints, or recruitment locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-10-27T20:53:23.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    Core content updated to inform users about funding-related operating status and current NIH Clinical Center openness; version updated from v3.1.0 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-06T08:10:21.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    Page now shows Revision: v3.1.0 and adds a batch of contact details (phone numbers and emails) for various individuals. Deletion indicates removal of v3.0.2.
    Difference
    0.1%
    Check dated 2025-09-29T04:44:02.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.